Teva Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints

Ensuring patient safety is extremely important to Teva Canada Limited and Teva Canada Innovation G.P.-S.E.N.C. (“Teva”, “we” and “us”) and we take the safe use of all our products seriously. Teva needs to be able to get in touch with people who contact Teva about our products in order to follow-up and obtain further information, give answers to requests or to send requested material. This Privacy Notice for Pharmacovigilence, Medical Information and Product Complaints describes how we collect and use “Personal Information” (which means information about an identifiable individual (“you”)) to help us fulfil our pharmacovigilance, product/quality complaint and medical inquiry obligations/requests to monitor and ensure the safety and quality of all our products, including medicines and medical devices that we sell or have in clinical development.

Scope of this Privacy Notice

This Privacy Notice applies to information we collect from or about you online (such as through our website, social media, chatbox or live chat), by phone, fax, e-mail or post, as part of Teva complying with any applicable adverse event, quality or medical inquiry or reporting regulations.

An “adverse event” means an unwanted, unintended or harmful event in relation to the use of a Teva product. With respect to medical devices, it also includes “incidents” and for cosmetics "serious undesirable effects", but for ease of reading, only the term “adverse event” will be used in this Privacy Notice. Pharmacovigilance legislation require us to take detailed records of every adverse event about which we become aware, to us to allow the event to be evaluated and collated with other adverse events recorded about that product.
If you are a patient, with your consent, we may also be provided with information about you by a third party reporting an adverse event that affected you. Such third parties may include medical professionals or healthcare providers, lawyers, relatives or other members of the public.

Information Regarding Personal Information Processing

We may collect Personal Information about both the patient who is the subject of an adverse event (“Patient”) and the individual who reports the adverse event (“Reporter”). If you contact us about an adverse event report affecting yourself, we will collect information about you as outlined below in your capacity as both the Reporter and the Patient.

 

How We Use and Share Personal Information

We may use and share Personal Information to:

• investigate the adverse event, quality complaint or medical inquiry;
• contact you for further information about the adverse event, quality complaint or medical inquiry you reported;
• collate the information about the adverse event, quality complaint or medical inquiry with information about other adverse events, quality complaint or medical inquiries received by Teva to analyse the safety of a batch, Teva product or active ingredient as a whole (such analysis is conducted only using pseudonymised information); and
• provide mandatory reports to national and/or regional authorities, in accordance with Teva’s legal requirements, so that they can analyse the safety of a batch, Teva product or active ingredient as a whole alongside reports from other sources (only pseudonymised information is provided to such authorities).

Our pharmacovigilance and quality obligations require us to review patterns across reports received from every country where we market our products. To meet these requirements, information provided as part of an adverse event or quality report is shared within Teva on a worldwide basis through Teva’s global database. This database is also the platform through which Teva uploads adverse event reports to various oversight authorities, including the Eudravigilance database (European Medicines Agency corporate system for managing and analysing information on suspected adverse reactions to medicines which have been authorised in the European Economic Area) and other similar databases as required by law. We also maintain a global medical inquiry database in order to answer your inquiries and internally manage these answers. However, your Personal Information is pseundonymised or de-identified when possible in order to protect your privacy.

Your Personal Information will be transferred (or otherwise made available) to certain third parties that provide services on our behalf. We use service providers to provide services such as data storage and processing . Our service providers are only provided with the information they need to perform their designated functions and are not authorized to use or disclose Personal Information for their own marketing or other purposes. As indicated above, our service providers may be located in Israel, the USA, Canada or other foreign jurisdictions.

We and our service providers may disclose your Personal Information if we are required or permitted by applicable law or legal process, which may include lawful access by foreign courts, law enforcement or other government authorities in the jurisdictions in which we or our service providers operate. For information about the manner in which we or our service providers treat Personal Information, please contact us as set out in the “Contact Information” section of the Privacy Notice.

Personal Information collected from you in accordance with this Privacy Notice may also be transferred to a third party in the event of a sale, assignment, transfer, or acquisition of the company or a specific product or therapeutic area, in which case we would require the buyer, assignee or transferee to treat that Personal Information in accordance with the purposes for which the Personal Information was collected and applicable data protection laws.

Further Information Regarding Pharmacovigilance

We may also share Personal Information with other pharmaceutical companies who are our co-marketing, co-distribution, or other license partners, where pharmacovigilance legal obligations for a product require such exchange of safety information.

Additionally, in some cases, as part of our market authorisation for a particular product, you may be enrolled in a patient safety programme, in which case we will provide you with further information, at the time of your enrolment, on our additional Personal Information practices (such as any additional information sharing or transfers) that would be applicable to you.

We share information with national, regional and international authorities, such as Health Canada and the European Medicines Agency in accordance with pharmacovigilance laws. We are unable to control their use of any information we share, however note that in these circumstances, we do not share any information that directly identifies any individual (such as names or contact information) and we only share pseudonymised information.

We may publish information about adverse events (such as case studies and summaries); in such a case, we will remove identifiers from and otherwise ensure that no individual can be easily recognized from the information published.

Your Rights

You may be entitled under applicable law to ask Teva for a copy of your Personal Information, to update or correct it, restrict its processing or otherwise withdraw your consent to its processing, or to ask us to transfer some of this information to other organisations. You may also have rights to object to some processing. These rights may be limited in some situations – for example, where we can demonstrate we have a legal requirement to process or keep your Personal Information. You may exercise these rights by contacting Teva’s Data Protection Officer (contact information below). Please note that we may require you to provide certain information, including proper identification, before we comply with any request listed above.

We hope that we can satisfy any queries you may have about the way in which we process your Personal Information. If you have any concerns about how we process your Personal Information, you can get in touch with Teva’s Data Protection Office (see below for contact information).

Security

Teva implements reasonable measures to secure Personal Information from accidental loss and from unauthorised access, use, alteration or disclosure. Additionally, we have implemented further information security measures including access controls, stringent physical security and robust information collection, storage & processing practices.

Changes to this Privacy Notice

If we decide to change the substance of this Privacy Notice materially, we will post those changes through a prominent notice.

Contact Information

If you have any concerns about how we process your Personal Information or wish to exercise any of your rights or wish to obtain other information about our Personal Information practices including information about our practices as they relate to our service providers located outside of Canada, , you can get in touch with Teva Data Protection Office by contacting us:

For Canada, you can contact our [Privacy Officer] at PrivacyOfficerCanada@tevacanada.com or TCI.PrivacyOfficer@tevapharm.com

We hope that we can satisfy any queries you may have about the way in which we process your Personal Information. However, if you have unresolved concerns, you also have the right to complain to the data protection authority in the location in which you live or work.

Effective date: October 2022